• 1  Prystowsky SD, Maumenee IH, Freeman RG, Herndon JH, Jr, Harrod MJ. A cutaneous marker in the Hunter syndrome a report of four cases. Arch Dermatol 1977;113(5):602–5. Cross Ref link Pubmed link
  • 2  Ochiai T, Suzuki Y, Kato T, et al. Natural history of extensive Mongolian spots in mucopolysaccharidosis type II (Hunter syndrome): a survey among 52 Japanese patients. J Eur Acad Dermatol Venereol 2007;21(8):1082–5. Cross Ref link Pubmed link
  • 3  Belcher RW. Ultrastructure of the skin in the genetic mucopolysaccharidoses. Arch Pathol 1972;94(6):511–18. Pubmed link
  • 4  Prasad VK, Kurtzberg J. Transplant outcomes in mucopolysaccharidoses. Semin Hematol 2010;47(1):59–69. Cross Ref link Pubmed link
  • 5  Wraith JE. Limitations of enzyme replacement therapy: current and future. J Inherit Metab Dis 2006;29(2–3):442–7. Cross Ref link Pubmed link
  • 6  Kanzaki T, Yokota M, Irie F, Hirabayashi Y, Wang AM, Desnick RJ. Angiokeratoma corporis diffusum with glycopeptiduria due to deficient lysosomal alpha‐N‐acetylgalactosaminidase activity. Clinical, morphologic, and biochemical studies. Arch Dermatol 1993;129(4):460–5. Cross Ref link Pubmed link
  • 7  Kornfeld M, Snyder RD, Wenger DA. Fucosidosis with angiokeratoma. Electron microscopic changes in the skin. Arch Pathol Lab Med 1977;101(9):478–85. Pubmed link
  • 8  Willems PJ, Gatti R, Darby JK, et al. Fucosidosis revisited: a review of 77 patients. Am J Med Genet 1991;38(1):111–31. Cross Ref link Pubmed link
  • 9  Arvio P, Arvio M, Kero M, Pirinen S, Lukinmaa PL. Overgrowth of oral mucosa and facial skin, a novel feature of aspartylglucosaminuria. J Med Genet 1999;36(5):398–404. Pubmed link
  • 10  Toussaint M, Worret WI, Drosner M, Marquardt KH. Specific skin lesions in a patient with Niemann‐Pick disease. Br J Dermatol 1994;131(6):895–7. Cross Ref link Pubmed link
  • 11  Lee RE. The fine structure of the cerebroside occurring in Gaucher's disease. Proc Natl Acad Sci USA 1968;61(2):484–9. Cross Ref link Pubmed link
  • 12  Grabowski GA. Phenotype, diagnosis, and treatment of Gaucher's disease. Lancet 2008;372(9645):1263–71. Cross Ref link Pubmed link
  • 13  Germain DP. Fabry disease. Orphanet J Rare Dis 2010;5:30. Cross Ref link Pubmed link
  • 14  Nakao S, Takenaka T, Maeda M, et al. An atypical variant of Fabry's disease in men with left ventricular hypertrophy. N Engl J Med 1995;333(5):288–93. Cross Ref link Pubmed link
  • 15  MacDermot KD, Holmes A, Miners AH. Anderson‐Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet 2001;38(11):750–60. Cross Ref link Pubmed link
  • 16  MacDermot KD, Holmes A, Miners AH. Anderson‐Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet 2001;38(11):769–75. Cross Ref link Pubmed link
  • 17  Orteu CH, Jansen T, Lidove O, et al. Fabry disease and the skin: data from FOS, the Fabry outcome survey. Br J Dermatol 2007;157(2):331–7. Cross Ref link Pubmed link
  • 18  Deegan PB, Baehner AF, Barba Romero MA, Hughes DA, Kampmann C, Beck M. Natural history of Fabry disease in females in the Fabry Outcome Survey. J Med Genet 2006;43(4):347–52. Cross Ref link Pubmed link
  • 19  Hashimoto K, Lieberman P, Lamkin N, Jr. Angiokeratoma corporis diffusum (Fabry disease). A lysosomal disease. Arch Dermatol 1976;112(10):1416–23. Cross Ref link Pubmed link
  • 20  Beratis NG, Varvarigou‐Frimas A, Beratis S, Sklower SL. Angiokeratoma corporis diffusum in GM1 gangliosidosis, type 1. Clin Genet 1989;36(1):59–64. Cross Ref link Pubmed link
  • 21  Nobeyama Y, Honda M, Niimura M. A case of galactosialidosis. Br J Dermatol 2003;149(2):405–9. Cross Ref link Pubmed link
  • 22  Goldblatt J, Beighton P. Cutaneous manifestations of Gaucher disease. Br J Dermatol 1984;111(3):331–4. Cross Ref link Pubmed link
  • 23  Mignot C, Doummar D, Maire I, De Villemeur TB. Type 2 Gaucher disease: 15 new cases and review of the literature. Brain Dev 2006;28(1):39–48. Cross Ref link Pubmed link
  • 24  Raddadi AA, Al Twaim AA. Type A Niemann‐Pick disease. J Eur Acad Dermatol Venereol 2000;14(4):301–3. Cross Ref link Pubmed link
  • 25  Qualman SJ, Moser HW, Valle D, et al. Farber disease: pathologic diagnosis in sibs with phenotypic variability. Am J Med Genet Suppl 1987;3:233–41. Cross Ref link Pubmed link
  • 26  Plummer C, Spring PJ, Marotta R, et al. Multiple symmetrical lipomatosis – a mitochondrial disorder of brown fat. Mitochondrion 2013;13(4):269–76. Cross Ref link Pubmed link
  • 27  Guallar JP, Vila MR, Lopez‐Gallardo E, et al. Altered expression of master regulatory genes of adipogenesis in lipomas from patients bearing tRNA(Lys) point mutations in mitochondrial DNA. Mol Genet Metab 2006;89(3):283–5. Cross Ref link Pubmed link
  • 28  Burlina AB, Dionisi‐Vici C, Bennett MJ, et al. A new syndrome with ethylmalonic aciduria and normal fatty acid oxidation in fibroblasts. J Pediatr 1994;124(1):79–86. Cross Ref link Pubmed link
  • 29  Tiranti V, Viscomi C, Hildebrandt T, et al. Loss of ETHE1, a mitochondrial dioxygenase, causes fatal sulfide toxicity in ethylmalonic encephalopathy. Nat Med 2009;15(2):200–5. Cross Ref link Pubmed link
  • 30  Viscomi C, Burlina AB, Dweikat I, et al. Combined treatment with oral metronidazole and N‐acetylcysteine is effective in ethylmalonic encephalopathy. Nat Med 2010;16(8):869–71. Cross Ref link Pubmed link
  • 31  Sevior KB, Hatamochi A, Stewart IA, et al. Mitochondrial A7445G mutation in two pedigrees with palmoplantar keratoderma and deafness. Am J Med Genet 1998;75(2):179–85. Cross Ref link Pubmed link
  • 32  Wedatilake Y, Brown R, McFarland R, et al. SURF1 deficiency: a multi‐centre natural history study. Orphanet J Rare Dis 2013;8(1):96. Cross Ref link Pubmed link
  • 33  Kubota Y, Ishii T, Sugihara H, Goto Y, Mizoguchi M. Skin manifestations of a patient with mitochondrial encephalomyopathy with lactic acidosis and strokelike episodes (MELAS syndrome). J Am Acad Dermatol 1999;41(3 Pt 1):469–73. Cross Ref link Pubmed link
  • 34  Rymen D, Jaeken J. Skin manifestations in CDG. J Inherit Metab Dis 2014;37(5):699–708. Cross Ref link Pubmed link
  • 35  Grunewald S. The clinical spectrum of phosphomannomutase 2 deficiency (CDG‐Ia). Biochim Biophys Acta 2009;1792(9):827–34. Cross Ref link Pubmed link
  • 36  Paine RS. The variability in manifestations of untreated patients with phenylketonuria (phenylpyruvic aciduria). Pediatrics 1957;20(2):290–302. Pubmed link
  • 37  Koch R, Burton B, Hoganson G, et al. Phenylketonuria in adulthood: a collaborative study. J Inherit Metab Dis 2002;25(5):333–46. Cross Ref link Pubmed link
  • 38  Levy HL, Milanowski A, Chakrapani A, et al. Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R‐BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III randomised placebo‐controlled study. Lancet 2007;370(9586):504–10. Cross Ref link Pubmed link
  • 39  Bohnert A, Anton‐Lamprecht I. Richner‐Hanhart's syndrome: ultrastructural abnormalities of epidermal keratinization indicating a causal relationship to high intracellular tyrosine levels. J Invest Dermatol 1982;79(2):68–74. Cross Ref link Pubmed link
  • 40  Rabinowitz LG, Williams LR, Anderson CE, Mazur A, Kaplan P. Painful keratoderma and photophobia: hallmarks of tyrosinemia type II. J Pediatr 1995;126(2):266–9. Cross Ref link Pubmed link
  • 41  Phornphutkul C, Introne WJ, Perry MB, et al. Natural history of alkaptonuria. N Engl J Med 2002;347(26):2111–21. Cross Ref link Pubmed link
  • 42  Introne WJ, Perry MB, Troendle J, et al. A 3‐year randomized therapeutic trial of nitisinone in alkaptonuria. Mol Genet Metab 2011;103(4):307–14. Cross Ref link Pubmed link
  • 43  Milligan A, Graham‐Brown RA, Burns DA, Anderson I. Prolidase deficiency: a case report and literature review. Br J Dermatol 1989;121(3):405–9. Cross Ref link Pubmed link
  • 44  Falik‐Zaccai TC, Khayat M, Luder A, et al. A broad spectrum of developmental delay in a large cohort of prolidase deficiency patients demonstrates marked interfamilial and intrafamilial phenotypic variability. Am J Med Genet B Neuropsychiatr Genet 2010;153B(1):46–56. Pubmed link
  • 45  Shrinath M, Walter JH, Haeney M, Couriel JM, Lewis MA, Herrick AL. Prolidase deficiency and systemic lupus erythematosus. Arch Dis Child 1997;76(5):441–4. Cross Ref link Pubmed link
  • 46  Erez A, Nagamani SC, Shchelochkov OA, et al. Requirement of argininosuccinate lyase for systemic nitric oxide production. Nat Med 2011;17(12):1619–26. Cross Ref link Pubmed link
  • 47  Fichtel JC, Richards JA, Davis LS. Trichorrhexis nodosa secondary to argininosuccinicaciduria. Pediatr Dermatol 2007;24(1):25–7. Cross Ref link Pubmed link
  • 48  Scriver CR, Mahon B, Levy HL, et al. The Hartnup phenotype: Mendelian transport disorder, multifactorial disease. Am J Hum Genet 1987;40(5):401–12. Pubmed link
  • 49  Baron DN, Dent CE, Harris H, Hart EW, Jepson JB. Hereditary pellagra‐like skin rash with temporary cerebellar ataxia, constant renal amino‐aciduria, and other bizarre biochemical features. Lancet 1956;271(6940):421–8. Cross Ref link Pubmed link
  • 50  Ryan AK, Bartlett K, Clayton P, et al. Smith‐Lemli‐Opitz syndrome: a variable clinical and biochemical phenotype. J Med Genet 1998;35(7):558–65. Cross Ref link Pubmed link
  • 51  Kelley RI, Hennekam RC. The Smith‐Lemli‐Opitz syndrome. J Med Genet 2000;37(5):321–35. Cross Ref link Pubmed link
  • 52  Azurdia RM, Anstey AV, Rhodes LE. Cholesterol supplementation objectively reduces photosensitivity in the Smith‐Lemli‐Opitz syndrome. Br J Dermatol 2001;144(1):143–5. Cross Ref link Pubmed link
  • 53  Houten SM, Kuis W, Duran M, et al. Mutations in MVK, encoding mevalonate kinase, cause hyperimmunoglobulinaemia D and periodic fever syndrome. Nat Genet 1999;22(2):175–7. Cross Ref link Pubmed link
  • 54  Drenth JP, Haagsma CJ, van der Meer JW. Hyperimmunoglobulinemia D and periodic fever syndrome. The clinical spectrum in a series of 50 patients. International Hyper‐IgD Study Group. Medicine (Baltimore) 1994;73(3):133–44. Cross Ref link Pubmed link
  • 55  Hoffmann GF, Charpentier C, Mayatepek E, et al. Clinical and biochemical phenotype in 11 patients with mevalonic aciduria. Pediatrics 1993;91(5):915–21. Pubmed link
  • 56  Göttle M, Prudente CN, Fu R, et al. Loss of dopamine phenotype among midbrain neurons in Lesch‐Nyhan disease. Ann Neurol 2014;76(1):95–107. Cross Ref link Pubmed link
  • 57  Lesch M, Nyhan WL. A familial disorder of uric acid metabolism and central nervous system function. Am J Med 1964;36:561–70. Cross Ref link Pubmed link
  • 58  Seymons K, De Moor A, De Raeve H, Lambert J. Dermatologic signs of biotin deficiency leading to the diagnosis of multiple carboxylase deficiency. Pediatr Dermatol 2004;21(3):231–5. Cross Ref link Pubmed link
  • 59  Wastell HJ, Bartlett K, Dale G, Shein A. Biotinidase deficiency: a survey of 10 cases. Arch Dis Child 1988;63(10):1244–9. Cross Ref link Pubmed link
  • 60  Wolf B, Heard GS, Weissbecker KA, McVoy JR, Grier RE, Leshner RT. Biotinidase deficiency: initial clinical features and rapid diagnosis. Ann Neurol 1985;18(5):614–17. Cross Ref link Pubmed link
  • 61  Van Wouwe JP. Clinical and laboratory diagnosis of acrodermatitis enteropathica. Eur J Pediatr 1989;149(1):2–8. Cross Ref link Pubmed link
  • 62  Neldner KH, Hambidge KM. Zinc therapy of acrodermatitis enteropathica. N Engl J Med 1975;292(17):879–82. Cross Ref link Pubmed link
  • 63  Kaler SG. Diagnosis and therapy of Menkes syndrome, a genetic form of copper deficiency. Am J Clin Nutr 1998;67(Suppl. 5):S1029–34.
  • 64  Tsukahara M, Imaizumi K, Kawai S, Kajii T. Occipital horn syndrome: report of a patient and review of the literature. Clin Genet 1994;45(1):32–5. Cross Ref link Pubmed link
  • 65  Kaler SG, Holmes CS, Goldstein DS, et al. Neonatal diagnosis and treatment of Menkes disease. N Engl J Med 2008;358(6):605–14. Cross Ref link Pubmed link
  • 66  Seyhan M, Erdem T, Selimoglu MA, Ertekin V. Dermatological signs in Wilson's disease. Pediatr Int 2009;51(3):395–8. Cross Ref link Pubmed link
  • 67  Merle U, Schaefer M, Ferenci P, Stremmel W. Clinical presentation, diagnosis and long‐term outcome of Wilson's disease: a cohort study. Gut 2007;56(1):115–20. Cross Ref link Pubmed link
  • 68  Wiggelinkhuizen M, Tilanus ME, Bollen CW, Houwen RH. Systematic review: clinical efficacy of chelator agents and zinc in the initial treatment of Wilson disease. Aliment Pharmacol Ther 2009;29(9):947–58. Cross Ref link Pubmed link
  • 69  Sprecher E. Familial tumoral calcinosis: from characterization of a rare phenotype to the pathogenesis of ectopic calcification. J Invest Dermatol 2010;130:652–60. Cross Ref link Pubmed link
  • 70  Touart DM, Sau P. Cutaneous deposition diseases. Part II. J Am Acad Dermatol 1998;39:527–44, quiz 45–6. Cross Ref link Pubmed link
  • 71  Parwani AV, Chan TY, Ali SZ. Significance of psammoma bodies in serous cavity fluid: a cytopathologic analysis. Cancer 2004;102:87–91. Cross Ref link Pubmed link
  • 72  Bai Y, Zhou G, Nakamura M, et al. Survival impact of psammoma body, stromal calcification, and bone formation in papillary thyroid carcinoma. Mod Pathol 2009;22:887–94. Cross Ref link Pubmed link
  • 73  Sprecher E. Familial tumoral calcinosis: from characterization of a rare phenotype to the pathogenesis of ectopic calcification. J Invest Dermatol 2010;130:652–60. Cross Ref link Pubmed link
  • 74  Benet‐Pages A, Orlik P, Strom TM, Lorenz‐Depiereux B. An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum Mol Genet 2005;14:385–90. Cross Ref link Pubmed link
  • 75  Ichikawa S, Imel EA, Kreiter ML, et al. A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis. J Clin Invest 2007;117:2684–91. Cross Ref link Pubmed link
  • 76  Topaz O, Shurman DL, Bergman R, et al. Mutations in GALNT3, encoding a protein involved in O‐linked glycosylation, cause familial tumoral calcinosis. Nat Genet 2004;36:579–81. Cross Ref link Pubmed link
  • 77  Topaz O, Indelman M, Chefetz I, et al. A deleterious mutation in SAMD9 causes normophosphatemic familial tumoral calcinosis. Am J Hum Genet 2006;79:759–64. Cross Ref link Pubmed link
  • 78  Bhattacharyya S, Sargent JL, Du P, et al. Egr‐1 induces a profibrotic injury/repair gene program associated with systemic sclerosis. PLOS One 2011;6:e23082. Cross Ref link Pubmed link
  • 79  Li CF, MacDonald JR, Wei RY, et al. Human sterile alpha motif domain 9, a novel gene identified as down‐regulated in aggressive fibromatosis, is absent in the mouse. BMC Genomics 2007;8:92. Cross Ref link Pubmed link
  • 80  Asou H, Matsui H, Ozaki Y, et al. Identification of a common microdeletion cluster in 7q21.3 subband among patients with myeloid leukemia and myelodysplastic syndrome. Biochem Biophys Res Commun 2009;383:245–51. Cross Ref link Pubmed link
  • 81  Chefetz I, Ben Amitai D, Browning S, et al. Normophosphatemic familial tumoral calcinosis is caused by deleterious mutations in SAMD9, encoding a TNF‐alpha responsive protein. J Invest Dermatol 2008;128:1423–9. Cross Ref link Pubmed link
  • 82  Hershkovitz D, Gross Y, Nahum S, et al. Functional characterization of SAMD9, a protein deficient in normophosphatemic familial tumoral calcinosis. J Invest Dermatol 2011;131:662–9. Cross Ref link Pubmed link
  • 83  Ghazvini‐Boroujerdi M, Clark J, Narula N, et al. Transcription factor Egr‐1 in calcific aortic valve disease. J Heart Valve Dis 2004;13:894–903. Pubmed link
  • 84  McCaffrey TA, Fu C, Du B, et al. High‐level expression of Egr‐1 and Egr‐1‐inducible genes in mouse and human atherosclerosis. J Clin Invest 2000;105:653–62. Cross Ref link Pubmed link
  • 85  Lammoglia JJ, Mericq V. Familial tumoral calcinosis caused by a novel FGF23 mutation: response to induction of tubular renal acidosis with acetazolamide and the non‐calcium phosphate binder sevelamer. Horm Res 2009;71:178–84. Cross Ref link Pubmed link
  • 86  Wraith JE. Mucopolysaccharidoses and oligosaccharidoses. In: Fernandes J, Saudubray J‐M, van den Berghe G, Walter JH, eds. Inborn Metabolic Diseases, 4th edn. Heidelberg: Springer, 2006:495–507
  • 87  Sarafoglou K, Hoffmann GR, Roth KS, eds. Pediatric Endocrinology and Inborn Errors of Metabolism. New York: McGraw‐Hill Education, 2009.